Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

Prospectus Supplement (April 2024 ATM)

BPTH_Prospectus-Supplement_20240404_ATM

SEC Form 8-K: Entry into a Material Definitive Agreement.

BPTH_Frm_8-K_20240404

SEC Form 424(b)5: Perspectus Supplement (To Prospectus dated June 14, 2022)

BPTH._424B5_20240327

SEC Form 8-K: Other events, Financial Statements and Exhibits

BPTH-_Form_8-K_20240327

SEC Form 8-K: Entry into Definitive Material Agreement

BPTH_8-K_20240326

SEC Form 8-K: Nasdaq delisting notification

BPTH_Form_8-K_Nasdaq_delisting_notification

SEC Form S-1 Amendment #1 Exhibits only filing

BPTH_S-1_A_2024-03-13

SEC Form 8-K: Regaining Nasdaq Compliance

BPTH_Form_8-K_2024_Nasdaq_Notice_re_Regaining_Compliance

SEC Form 8-K: Press Release dated March 8, 2024

BPTH_-Form-8-K_20240308

SEC Form S-1

BPTH__S-1_20240308

Bio-Path Holdings

All Rights Reserved

Office:

625 Stanwix Street
Pittsburgh, PA, 15222

T: (630) 708-0750

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Scientifc Advisory Board
    • Directors
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us